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Abstract
Introduction: Activation status of the phosphatidylinositol 3-kinase (PI3K) pathway in breast cancer brain
metastases (BCBMs) is largely unknown. We examined expression of phospho(p)-AKT, p-S6, and phosphatase and
tensin homologue (PTEN) in BCBMs and their implications for overall survival (OS) and survival after BCBMs.
Secondary analyses included PI3K pathway activation status and associations with time to distant recurrence (TTDR)
and time to BCBMs. Similar analyses were also conducted among the subset of patients with triple-negative
BCBMs.
Methods: p-AKT, p-S6, and PTEN expression was assessed with immunohistochemistry in 52 BCBMs and 12
matched primary BCs. Subtypes were defined as hormone receptor (HR)+/HER2-, HER2+, and triple-negative (TNBC).
Survival analyses were performed by using a Cox model, and survival curves were estimated with the Kaplan-Meier
method.
Results: Expression of p-AKT and p-S6 and lack of PTEN (PTEN-) was observed in 75%, 69%, and 25% of BCBMs.
Concordance between primary BCs and matched BCBMs was 67% for p-AKT, 58% for p-S6, and 83% for PTEN.
PTEN- was more common in TNBC compared with HR+/HER2- and HER2+. Expression of p-AKT, p-S6, and PTEN-
was not associated with OS or survival after BCBMs (all, P > 0.06). Interestingly, among all patients, PTEN- correlated
with shorter time to distant and brain recurrence. Among patients with TNBC, PTEN- in BCBMs was associated with
poorer overall survival.
Conclusions: The PI3K pathway is active in most BCBMs regardless of subtype. Inhibition of this pathway
represents a promising therapeutic strategy for patients with BCBMs, a group of patients with poor prognosis and
limited systemic therapeutic options. Although expression of the PI3K pathway did not correlate with OS and
survival after BCBM, PTEN- association with time to recurrence and OS (among patients with TNBC) is worthy of
further study.
Introduction
The incidence of brain metastases (BMs) is approxi-
mately 15% among women newly diagnosed with meta-
static breast cancer (BC) [1]. This figure likely
underestimates the true incidence, as autopsy studies
report a 30% incidence of BMs among women with
advanced disease [2]. Current therapeutic interventions
include corticosteroids, whole-brain radiotherapy, neuro-
surgical resection, stereotactic radiosurgery, and sys-
temic chemotherapy [3]. Despite these treatment
strategies, prognosis among patients with BCBMs
remains poor, with a median overall survival of approxi-
mately 6 months [4,5]. Although targeted agents show
promise in the treatment of advanced extracranial BC,
challenges in delivery of these agents to the central ner-
vous system (CNS) include properties inherent to the
blood barrier (that is, efflux mechanisms) and our
incomplete understanding the biology underlying
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BCBMs. Moreover, optimal therapeutic targets within
BCBM are largely unknown.
Previous studies indicate that the phosphatidylinosi-
tol 3-kinase (PI3K) pathway plays a critical role in the
initiation and progression of human BC, and altera-
tions in this pathway have been identified in approxi-
mately 50% of these tumors [6,7]. PI3K pathway
activation occurs in response to extracellular signals
via either growth-factor receptor or integrin pathways.
On its recruitment to the cellular membrane via
receptor-mediated activation, the p110a catalytic sub-
unit of PI3K phosphorylates phosphatidylinositol-4,5-
bisphosphate (PIP2) at the 3’ position of the inositol
ring, generating PIP3 [8]. PIP3 recruits phospholipid-
binding domain containing proteins, particularly AKT,
to the plasma membrane. Phosphorylated (p-)AKT,
the primary downstream effector of PI3K signaling,
moves from the cytoplasm to the nucleus to initiate
its downstream effects. This cascade, including activa-
tion of the mammalian target of rapamycin (mTOR)
and its downstream effectors, p70S6 kinase and 4E-
binding protein-1, affects a number of cellular pro-
cesses, including proliferation and motility, which
clinically translate into endocrine and chemotherapy
resistance and worse cancer-specific survival [6,9-12].
The PI3K/AKT pathway is negatively regulated by
PTEN (phosphatase and tensin homologue), a lipid
phosphatase that removes the 3-phosphate from PI
(3,4)P2 and PI(3,4,5)P3, thus inactivating the signaling
cascade [13]. Therefore, loss of PTEN contributes to
the activation of the PI3K/AKT signaling cascade
through inhibition of degradation of both PI(3,4)P2
and PI(3,4,5)P3.
To date, alterations and activation of the PI3K/AKT
pathway are well established in the initiation and pro-
gression of extracranial human BC [6,8-10,14,15]. How-
ever, the contribution of this important signaling
pathway to the pathogenesis of BCBMs has yet to be
fully elucidated. This is of clinical importance as small-
molecule inhibitors of the PI3K/AKT/mTOR pathway
are in development and show promising activity in the
treatment of primary brain tumors, suggesting sufficient
blood-brain barrier penetration to elicit therapeutic
effects [16,17]. In this study, we quantitated the expres-
sion of the PI3K pathway biomarkers p-AKT, p-S6, and
PTEN, and evaluated the prognostic implications, pri-
marily overall survival (OS) and survival after BCBMs,
of PI3K activation status in BCBMs. As secondary,
exploratory end points, we evaluated the associations
between PI3K pathway activation and time to distant
recurrence (TTDR) and time to BCBM. Finally, similar
analyses were also conducted among the subset of
patients with triple-negative BCBM.
Materials and methods
Patients
BCBMs (n = 52), including a subset with matched pri-
mary BCs (n = 12), from 52 patients treated at the Uni-
versity of North Carolina at Chapel Hill (UNC) (52%)
and Duke University (48%) between 1991 and 2008,
were studied. Clinical data, including age, race, stage of
primary BC at diagnosis (as per the 2003 Sixth Edition
of the American Joint Committee on Cancer [AJCC]),
treatment history (including local and systemic therapies
in the adjuvant and metastatic settings), recurrence, and
vital status were available for 50 patients. Given the ret-
rospective nature of clinical data collection, complete
information was not available for all 50 patients; thus,
denominators may vary throughout the article. This
study was approved, and waivers of consent were
granted by Institutional Review Boards at both UNC
and Duke.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on 5-μm
formalin-fixed, paraffin-embedded tissue sections on
coated glass slides by using a Dako Autostainer (DakoCy-
tomation, Carpinteria, CA). Monoclonal antibodies were
applied for 30 to 60 minutes at room temperature (with
the exception of HER2, which was incubated overnight at
4°C) and detected by using avidin-biotin chemistry (Vec-
tastain Elite Kit 6102; Vector, Burlingame, CA) and dia-
minobenzidine (Innovex NB314SB; Innovex Biosciences,
Richmond, CA) as chromogen. Signal contrast was maxi-
mized by counterstaining with hematoxylin (DakoCyto-
mation Mayer hematoxylin S3309), rinsing in deionized
water, and placement in a bluing solution (Richard-Allan
Scientific 7301; Richard-Allan Scientific, Kalamazoo, MI).
The following primary antibodies and dilutions were
used: p-AKT (Ser473, 1:10, Cell Signaling, Danvers, MA);
PTEN clone 6H2.1 (1:25; Cascade Biosciences, Winche-
ster, MA); p-S6 ribosomal protein (1:50, Ser235/236; Cell
Signaling); ER clone 1D5 (1:50; Dako), PR clone 16 (1:70;
Vision BioSystems, Norwell, MA); and HER2 clone CB11
(1:100; BioGenex, San Ramon, CA). For each antibody,
primary breast tumor tissue was used as a positive con-
trol. Technical negative controls omitting the primary
antibody using primary breast tumor tissue were also
used. IHC was performed on all 52 cases for p-AKT, p-
S6, and PTEN. IHC for ER, PR, and HER2 expression
was additionally performed on 38 cases. Because of lim-
ited tissue, four cases were stained for HER2 only, and
three cases were stained for ER and PR only.
Immunohistochemistry scoring
IHC stains were scored by two surgical pathologists (KF
and CL). Nuclear ER and PR staining were scored from
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0 to 8 by using the Allred system [17], and Allred scores
of 0 to 2 and 3 to 8 were defined as negative and posi-
tive, respectively. HER2 was scored by using the current
American Society of Clinical Oncology ASCO)/College
of American Pathologists (CAP) guidelines [18]. Mem-
branous immunoreactivity was scored (0 and 1+ indi-
cates negative; 2+, indeterminate; and 3+, positive for
overexpression), and the percentage of tumor cells stain-
ing positive was visually estimated.
For p-AKT, p-S6, and PTEN, an H score was calcu-
lated by multiplying the fraction of positively stained
tumor (percentage) by staining intensity (0, 1+, 2+, or 3
+). In subsequent statistical analyses, H scores were clas-
sified as negative (0 to 9), low (10 to 100), medium (101
to 200), or high (201 to 300) [18].
Identification of breast cancer subtypes
BC subtype was defined by IHC receptor status of the
BCBM as follows: Hormone receptor (ER and/or PR)
HR+/HER2-, triple-negative (ER-/PR-/HER2-, TN), and
HER2+. In five BCBM cases for which ER, PR, and
HER2 IHC data were not available, receptor status of
the BCBM was obtained per the clinical database and
was used to assign subtype. In three of five cases in
which HER2 re-staining was indeterminate (IHC = 2+),
HER2 classification was based on available clinical data
including either IHC and/or FISH (fluorescence in situ
hybridization). In the other two cases, HER2 2+ was
classified as negative for the purposes of this analysis.
Gene-expression microarray analysis
Normalized gene-expression data from two publicly
available datasets [19,20] were evaluated. In Harrell et
al. [19] (GSE26338), we analyzed the expression of
PTEN in a combined cohort of 855 primary BC patients
that were followed, and the first site of distant recur-
rence was retrospectively annotated, including a subset
of 42 patients in whom the first site of relapse (or one
of the first sites) was the brain. The intrinsic molecular
subtype calls were used as provided in Harrell et al.
[19]. In Zhang et al. [20] (GSE14018), we evaluated the
expression of PTEN across 36 unpaired BC brain, liver,
bone, and lung metastasis samples. In both datasets, all
PTEN probes were averaged into a single expression
value.
Statistical analysis
The Kaplan-Meier method and log-rank test were used
to compare differences among survival curves, and Cox
regression analysis was used to evaluate possible predic-
tors in the time-to-event outcomes. Overall survival
(OS) was defined as the time from diagnosis of primary
BC to death or last contact. CNS-specific survival (CNS
survival) was defined as the time from the date of
BCBM to the date of death or last follow-up. Time to
distant recurrence (TTDR) was defined as the time from
primary BC diagnosis to date of distant recurrence.
Time to CNS recurrence (TTCNS) was defined as the
time from primary BC diagnosis to date of CNS metas-
tases; for those patients whose initial distant recurrence
included the CNS, this time was the same as the time to
distant recurrence. Differences in PTEN gene expression
across the various intrinsic molecular subtypes and
between brain metastases and other distant metastastic
sites was evaluated by using a Wilcoxon rank sum test.
Associations with relapse-free survival were evaluated by
using the log-rank test, and Cox regression; PTEN
expression was categorized as low/medium or high
based on combining the lower two tertiles. Statistical
analyses were performed with SAS 9.2 statistical soft-
ware (SAS Institute, Inc., Cary, NC) and R v.2.8.1 http://
cran.r-project.org.
Results
Patient and tumor characteristics
The clinical characteristics of the study population are
presented in Table 1. The median age at diagnosis of
primary BC was 48 years (range, 26 to 72 years). Sixty-
eight percent of patients were Caucasian, 30%, African-
American, and 2%, other ethnicities. Fifty percent of
patients were Stage II, and 29% were Stage III at the
time of surgery for primary BC.
BC subtype was assigned based on IHC staining of
BCBM for 43 patients, and subtype distribution was as
follows: 28% HR+/HER2-, 44% TN, and 28% HER2+.
Subtype concordance between primary BC and asso-
ciated BCBM was 57% (four of seven). Of the three
cases that were discordant, two HER2+ primary BC
lacked HER2 staining in the matched BCBM, whereas
one TN primary BC gained HR positivity (HR+/HER2-)
in the matched BCBM.
Overview of systemic and local therapies
Ninety-two percent of patients received systemic che-
motherapy with curative intent (29% and 71% in the
neoadjuvant and adjuvant settings, respectively) for their
primary BC (Table 1), whereas 55% (HR+/HER2-)
received endocrine therapy, and 17% (HER2+) received
trastuzumab.
In the metastatic setting, 95% (36 of 38) of patients
received some form of systemic therapy; with 32%
receiving one line, and 63% receiving two or more lines
of therapy. Seventeen percent (six of 35) received sys-
temic therapy both before and after development of
CNS metastases; 20% only before and 63% only after
diagnosis of BCBM. Therapies in the metastatic setting
included the following: chemotherapy (74%), endocrine
therapy (70%, HR+ only), and HER2-directed therapy
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(67%, HER2+ only). Fifty-three percent received cranial
radiation (XRT) for BCBM; 9% received radiosurgery.
No difference in OS or CNS survival was seen between
those who did or did not receive cranial XRT (P = 0.7,
0.5).
Expression of PI3K pathway biomarkers in breast cancer
brain metastases
Activation of the PI3K pathway in BCBM was deter-
mined by evaluating the expression of p-AKT, p-S6, and
PTEN with IHC. Expression of p-AKT and p-S6 was
positive (H score, 10 to 300) in 75% and 69% of BCBM,
respectively (Table 2a and Figure 1). Twenty-five per-
cent of BCBMs lacked PTEN expression (PTEN-, H
score, 0 to 9).
No significant association was found between BCBM
subtype and PI3K pathway status for p-AKT, p-S6, or
PTEN (all P > 0.3). Interestingly, PTEN- was more fre-
quent among the TN BCBM (seven of 19, 37%) com-
pared with HR+/HER2- (two of 12, 17%) and HER2+
(three of 12, 25%) BC (P = 0.3). Concurrent PI3K
pathway activation (p-AKT and/or p-S6 H score ≥10)
and PTEN- (H score, 0 to 9) was present in 15% of 52
BCBMs. A larger proportion (five of 19, 26%) of BCBMs
arising from patients with TNBC showed this IHC pat-
tern, compared with 8% (one of 12) of the HR+/HER2-
and 17% (two of 12) of the HER2+ patients (P = 0.5).
Concordance of PI3K expression between brain
metastases and primary breast tumors
PI3K pathway biomarkers status in primary BC and
their matched BCBM was concordant in 67%, 58%, and
83% of 12 cases for p-AKT, p-S6, and PTEN, respec-
tively (Table 3), and both gains and losses of which
were evident for each biomarker evaluated.
Survival outcomes according to breast cancer subtype
Prior reports suggested that BC prognosis is dependent
on IHC subtype, as TN portends inferior outcome
regardless of systemic therapy [21-24]. The prognostic
implication of IHC subtype within BCBMs was exam-
ined. The median follow-up for survivors was 7 years,
and 74% (37 of 50) of patients have died. As shown in
Figure 2, median overall survival was 6.1 years, 3.4
years, and 9.2 years for HR+/HER2-, TN, and HER2+
subtypes, respectively (P = 0.005). Median survival after
BCBM diagnosis was 1.8, 0.64, and 2.3 years for HR
+/HER2-, TN, and HER2+, respectively (P = 0.004, Fig-
ure 3). Median time to distant recurrence was 3.7, 1.8,
and 3.2 years for HR+/HER2-, TN, and HER2+, respec-
tively (P = 0.11), and median time to CNS recurrence
was 3.7, 1.9, and 3.8 years for HR+/HER2-, TN, and
HER2+, respectively (P = 0.2, data not shown).
Survival outcomes by expression of p-AKT, p-S6, and
PTEN
The prognostic implications of p-AKT, p-S6, and PTEN
expression in BCBMs were evaluated. Expression of p-
AKT, p-S6, and PTEN (H score, < 10 versus ≥10) was
not associated with the primary outcome of overall sur-
vival or survival after BCBMs (P ≥ 0.06 for all analyses;
data not shown). In secondary analyses, neither
Table 1 Patient, tumor, and treatment characteristics
Characteristic All patients
N (%)
No. of patients 50
Median age 48 (26-72 years)
< 40 years 12 (24%)
≥40 years 38 (76%)
Ethnicity
Caucasian 34 (68%)
African American 15 (30%)
Other 1 (2%)
Stage N = 34
I 4 (12%)
II 17 (50%)
III 10 (29%)
IV 3 (9%)
IHC subtype N = 43
HR+/HER2- 12 (28%)
HR-/HER2- (TN) 19 (44%)
HER2+ 12 (28%)
Systemic therapy for primary BC
Chemotherapy 44/48 (92%)
Endocrine therapy (for HR+/HER2-) 6/11 (55%)
Trastuzumab (for HER2+) 2/12 (17%)
Systemic therapy for metastatic BC
Chemotherapy 28/38 (74%)
Endocrine therapy (for HR+/HER2-) 7/10 (70%)
Her2-directed therapy (for HER2+) 6/9 (67%)
BCBM therapy N = 47
Cranial XRT 25 (53%)
Radiosurgery 4 (9%)
Table 2 Expression of PI3K pathway biomarkers in breast
cancer brain metastases
H score PTEN p-AKT p-S6
Negative
(0 to 9)
13 (25%) 13 (25%) 16 (31%)
Low
(10 to 100)
19
(37%)
19
(37%)
25
(48%)
Medium
(101 to
200)
7 (13%) 39
(75%)
10
(19%)
39
(75%)
7 (13%) 36
(69%)
High
(201 to
300)
13
(25%)
10
(19%)
4 (8%)
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expression of p-AKT nor p-S6 was associated with time
to distant or CNS recurrence (P ≥ 0.05 for all analyses,
data not shown). Although not associated with an infer-
ior overall survival from primary BC diagnosis (5.1 ver-
sus 5.7 years; P = 0.16) or survival after BCBM (2.0
versus 1.4 years, P = 0.9; data not shown), PTEN-
BCBM was associated with shorter time to both distant
(2.2 versus 3.1 years; P = 0.02; Figure 4) and CNS recur-
rence (2.5 versus 3.4 years; P = 0.06; Figure 5) even
when stratified by TNBC (see later section) in explora-
tory analyses. Moreover, 5-year freedom from distant
recurrence were 0 and 22% (95% confidence interval
(CI), 10% to 36%) for PTEN- versus PTEN+ BCBMs.
Similarly, 5-year freedom from CNS recurrence was
7.6% (95% CI, 0.5% to 29%) and 24% (95% CI, 12% to
39%) for these two groups, respectively.
To confirm that these results were not influenced by
receipt of systemic therapy, we evaluated the proportion
of patients who received treatment by PTEN status. No
difference was found in receipt of systemic chemother-
apy, either in the curative (10 of 12, 83% versus 34 of
36, 94%; P = 0.26) or advanced setting (eight of nine,
89%, versus 20 of 29, 69%; P = 0.4), between patients
with either PTEN- or PTEN+ BCBM, respectively. Inter-
estingly, a higher proportion of PTEN- BCBM patients
(nine of 11, 82%) received cranial XRT for BCBM com-
pared with those with PTEN+ BCBM (16 of 26, 44%; P
= 0.04).
Figure 1 Expression of p-AKT, pS6, and PTEN by immunohistochemistry in a primary breast tumor and its paired brain metastasis.
Table 3 Concordance of PI3K biomarkers between
primary breast tumors and matched breast cancer brain
metastases (n = 12)
Biomarker Gain Loss Concordance
PTEN 1 (8.3%) 1 (8.3%) 10 (83.3%)
p-AKT 2 (16.6%) 2 (16.6%) 8 (66.6%)
p-S6 3 (25.0%) 2 (16.6%) 7 (58.3%)
Figure 2 Overall survival, defined as time from primary breast
cancer diagnosis to death, by breast cancer subtype.
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Survival by PTEN status among patients with triple-
negative breast cancer
Recognizing the association between TNBC and PTEN
expression, we evaluated the prognostic significance of
PTEN expression within the TN BCBM subset as a sec-
ondary and exploratory outcome. PTEN- TN BCBMs
were associated with inferior overall survival (1.7 years)
compared with PTEN+ BCBM (4.7 years; P = 0.03;
Figure 6). PTEN status had no significant effect on over-
all survival in patients with non-TN BCBM (PTEN-, 8.2
years; PTEN+, 7.1 years; P = 0.8, data not shown). No
significant effect of PTEN status on time to distant
recurrence, time to CNS recurrence, or survival after
BCBM was noted for patients with either TN or non-
TN BCBM (all P ≥ 0.5; data not shown). However, time
Figure 3 Survival after breast cancer brain metastases as
determined by breast cancer subtype.
Figure 4 Time to distant recurrence from primary breast
cancer diagnosis by PTEN negativity versus positivity as
determined by brain metastases immunohistochemistry.
Figure 5 Time to central nervous system recurrence from
primary breast cancer diagnosis by PTEN negativity versus
positivity, as determined by brain metastases
immunohistochemistry.
Figure 6 Overall survival by PTEN status as determined by
brain metastases immunohistochemistry in patients with
triple-negative breast cancer.
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to distant recurrence (1.3 versus 1.9 years; P = 0.08) and
time to CNS recurrence (1.3 versus 2.5; P = 0.11) was
shorter for patients with PTEN-, TN BCBM.
Impact of subtype and PTEN status on patient outcome
Consistent with the Kaplan-Meier analyses, the TN IHC
subtype was found to be associated with worse overall
survival, time to distant and CNS recurrence, and survi-
val after BCBM in univariable Cox regression analyses
(all, P ≤ 0.06) (Table 4). PTEN- was associated with
more rapid time to distant recurrence (hazard ratio
(HR), 2.2; P = 0.025); a borderline association between
PTEN- and shorter time to CNS recurrence was
observed (HR, 1.8; P = 0.07).
On multivariable Cox regression analyses, the associa-
tion between subtype and overall survival, time to dis-
tant recurrence, and survival after CNS metastases
remained significant when controlling for PTEN status
(all, P ≤ 0.04). Similarly, the association between PTEN-
and shorter time to distant recurrence (HR, 2.4; P =
0.02) and time to CNS recurrence (HR, 2; P = 0.06)
remained when controlling for subtype among patients
with BCBMs.
Evaluation of PTEN gene expression across the intrinsic
molecular subtypes and brain metastases
To further explore the association of PTEN- with triple-
negative disease and brain metastases, we interrogated
two publicly available gene-expression microarray data
sets that included: (a) 855 primary breast cancers with
annotated intrinsic subtype and relapse-free survival
data [19], and (b) 36 unpaired brain, lung, liver, and
bone BC metastases [20]. First, we evaluated the expres-
sion of the PTEN gene across the intrinsic molecular
subtypes in the Harrell et al. [19] dataset. As shown in
Figure 7a, basal-like tumors showed an overall lower
expression of PTEN compared with the other subtypes
of BC. Second, we observed that PTEN expression was
expressed at lower levels in BCBMs compared with
other distant metastatic sites (Figure 7b). Although we
cannot rule out that this observation is due to the fact
that these brain metastases were largely of the basal-like
subtype, whereas bone and liver metastasis were more
of the luminal and HER2-enriched subtypes, these data
support the association of lower levels of PTEN, basal-
like tumors, and the development of brain metastases.
Survival outcomes based on PTEN gene expression
Further to explore the association of PTEN- with poor
outcome, we evaluated the Harrell et al. [19] combined
microarray data set. In all patients (n = 855), lower levels
of PTEN expression were found to be associated with
poor prognosis at 5 years (P = 0.002), even when adjusted
for ER status (P = 0.012) and ER status plus intrinsic
molecular subtype (P = 0.025; Figure 8a). This suggests
that PTEN is not just recapitulating the poor prognosis
of the basal-like subtype, and supports our IHC-based
findings that lack of PTEN expression is also found in the
other tumor types. Moreover, in the subset of patients
that relapsed to the brain in the first 5 years (n = 42),
lower levels of PTEN expression were found to be asso-
ciated with a shorter time to brain recurrence (1.6 versus
3.4 years; P = 0.003), even when adjusted for ER status (P
= 0.001) and ER status plus subtype (P = 0.0003; Figure
8b). Finally, no association of S6K and AKT-1, -2, and -3
genes with outcome was observed (data not shown).
Discussion
BCBMs represent one of the most challenging aspects in
the clinical care of patients with advanced BC. Not only
does intracranial recurrence limit survival, but asso-
ciated symptoms also decrease functional status, limit
independence, and negatively affect quality of life. No
approved systemic therapies are available to treat
patients with BCBMs, and it is unclear whether thera-
peutic targets, such as PI3K, differ between primary BC
and BCBMs. In the present study, we explored the
expression and prognostic implications of a panel of
PI3K-pathway biomarkers, p-AKT, p-S6, and PTEN, in
52 BCBMs and 12 matched primary BCs. Our central
goal was to improve our current understanding of the
complex biology underlying BCBMs in hopes of guiding
the future use of targeted agents to treat this aggressive
disease. Our results show that the PI3K pathway is
active in most BCBMs, regardless of IHC subtype; how-
ever, activation status does not appear to affect overall
survival or survival after BCBMs in this cohort of
patients. Interestingly, our secondary analyses indicate
Table 4
Univariable analyses Multivariable analyses
OS TTDR TTCNS OS CNS OS TTDR TTCNS OS CNS
Variable HR P HR P HR P HR P HR P HR P HR P HR P
PTEN
(H score, negative vs. positive)
1.7 0.16 2.2 0.025 1.8 0.07 0.95 0.9 1.9 0.1 2.4 0.02 2 0.06 0.93 0.86
Subtype
(TN vs. non-TN)
3.1 0.003 1.9 0.04 1.8 0.06 3.2 0.003 3.2 0.002 2 0.04 1.8 0.06 3.2 0.003
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that the lack of PTEN expression may have prognostic
value, independent of subtype. Moreover, among
patients with aggressive TN BCBM, lack of PTEN
expression may also be associated with worse overall
survival.
Although alterations of the PI3K pathway are fre-
quently observed in primary BC [25], different
mechanisms of pathway activation exist [26]. Among
them, activating PIK3CA mutations have been identi-
fied in about 15% to 30% of breast tumors and are
more commonly associated with ER+ disease [27-31].
Conversely, alternative mechanisms of PI3K pathway
activation, such as loss of PTEN and loss of the
tumor-suppressor inositol polyphosphate 4-
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Figure 7 Evaluation of PTEN gene expression in breast cancer samples from two publicly available data sets [19,20]. (a) PTEN expression
across the intrinsic molecular subtypes of 855 primary tumors of the combined cohort in Harrell et al. [19]. (b) PTEN expression in a panel of
unpaired breast cancer brain metastases (n = 7) and other distant sites (n = 29). The colored boxes represent the interquartile range (IQR); the
bar indicates the median value; whiskers show the 1.5 × IQR.
Figure 8 Evaluation of PTEN gene expression in primary tumors with outcome at 5 years in Harrell et al. [19] combined data set. (a)
Relapse-free survival in the entire data set (n = 855) based on PTEN expression. (b) Time to brain recurrence (as the first site of relapse) based
on PTEN expression in the subset of patients that relapse to the brain in the first 5 years (n = 42). In both survival analyses, tumors in the highest
PTEN expression tertile of the entire data set were identified as high PTEN expressers, and the rest, as low PTEN expressers. P values shown here
have been adjusted for ER status and intrinsic molecular subtype.
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phosphatase type II (INPP4B), are more commonly
associated with basal-like BC [27,32-37]. Although our
data indicate that PI3K pathway activation in BCBM is
not entirely subtype specific, lack of PTEN expression
was more commonly observed in the TN and basal-
like subtypes when compared with the other tumor
types. Given that brain metastases across subtypes
were included in this study, multiple mechanisms of
PI3K activation (that is, PIK3CA mutations, PTEN
loss, and/or INPP4B loss) may be responsible for the
high levels of PI3K pathway activation observed in this
cohort. Future studies aimed at identifying subtype-
specific mechanisms of PI3K activation are certainly
warranted, both in primary BC and BCBM, to refine
our current understanding of the biologic processes
driving this disease process.
The role of PI3K-pathway activation as a prognostic
and/or predictive biomarker is under investigation.
Although our primary analyses did not reveal associa-
tions between PI3K-pathway activation and overall sur-
vival or survival after BCBM, several secondary analyses
are worthy of discussion. Our exploratory analysis indi-
cates PTEN may be prognostic, with lack of PTEN
expression being associated with more rapid time to dis-
ease recurrence (across subtypes) and worse overall sur-
vival in the TN subset of patients [38]. Interestingly, of
the three biomarkers evaluated in this study, PTEN
showed the highest concordance (83%) between
matched primary BC and BCBM. In the clinical setting,
biologic specimens from brain metastases are not com-
monly available, as resection is generally reserved for
solitary lesions, and biopsies are reserved for cases with
equivocal radiographic findings. Given the high concor-
dance of PTEN status between primary BCs and their
BCBMs, PTEN status in primary breast tumors may also
be prognostic, and potentially predictive of distant and
CNS recurrence. Confirming these findings in a large,
unselected cohort of patients with primary breast tumor
tissue available for PTEN testing would certainly be of
value.
We recognize that the data presented in this study
have several limitations. First, all patients included in
this study underwent a neurosurgical procedure, so the
population studied here might not be representative of
all patients with BCBMs. Second, the sample size in this
study is small, but comparable to previously reported
studies evaluating BCBM tissues [39]. Although this is
the largest study evaluating PI3K activation in BCBM
tissues to date, subset analyses should be interpreted
with caution because of the small sample size and multi-
ple comparisons. A laudable future goal would be to
validate these findings in a larger cohort; however, the
inherent difficulty of obtaining brain metastasis tissues
remains an obstacle. Thus, the development of clinically
annotated brain metastases and primary BC tissue repo-
sitories housing both paraffin-embedded and fresh, fro-
zen tissues should be a priority among the scientific
community.
Finally, we used an IHC definition to identify the
intrinsic molecular subtypes based on ER, PR, and
HER2 status. We recognize that considerable discor-
dance may exist between subtype assignment by IHC
biomarkers and molecular profiling [40]. However, simi-
lar results were observed when we evaluated publicly
available gene-expression data in more than 800 tumors
in which molecular profiling had been performed
[19,20]. Overall, this genomic analysis supports our IHC
findings, in which PTEN expression was associated with
time to distant and brain recurrence, basal-like tumors,
and the development of BCBM.
Conclusions
In summary, results of this study indicate that the PI3K
pathway is active in the majority of BCBMs across the
spectrum of IHC subtypes. Although expression of the
PI3K pathway did not correlate with OS and survival
after BCBM, loss of PTEN may hold prognostic and/or
predictive value among this group of very high risk
patients. Presently, small-molecule inhibitors of the
PI3K pathway are in clinical development to treat multi-
ple malignancies, including BC [41,42], and several cross
the blood-brain barrier. Thus, inhibition of the PI3K
pathway represents a promising therapeutic strategy for
patients with BCBMs, with the ultimate goal of improv-
ing outcome and quality of life for patients diagnosed
with this devastating disease.
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